Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma

Purpose To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review. Methods We performed a systematic literature review to identify factors impacting the...

Full description

Saved in:
Bibliographic Details
Published inJournal of cancer research and clinical oncology Vol. 151; no. 7; pp. 203 - 18
Main Authors Schleifenbaum, Julia K., Heger, Jan-Michel, Jost, Jonas, Rosato, Umberto, Riou, Sybille, Borchmann, Peter, Walzer, Stefan, Mahlich, Jörg
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 07.07.2025
Springer Nature B.V
Springer
Subjects
Antigens
B-cell lymphoma
Cancer Research
CAR-T
Cell therapy
Chemotherapy
Chimeric antigen receptors
Cytokine storm
DLBCL
Hematology
Humans
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Internal Medicine
Literature reviews
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Large B-Cell, Diffuse - therapy
Medical prognosis
Medical Subject Headings-MeSH
Medicine
Medicine & Public Health
Neurotoxicity
Oncology
Patients
Prognosis
Prognostic factors
Receptors, Chimeric Antigen - immunology
Response rates
Review
Safety
Systematic literature review
Systematic review
Treatment Outcome
United States > US
DLBCL
CAR-T
Prognostic factors
Systematic literature review
Online AccessGet full text
ISSN1432-1335
0171-5216
1432-1335
DOI10.1007/s00432-025-06249-z

Cover

Abstract Purpose To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review. Methods We performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type. Results This review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels. Conclusion The findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
AbstractList To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review.PURPOSETo identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review.We performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type.METHODSWe performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type.This review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels.RESULTSThis review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels.The findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.CONCLUSIONThe findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review. We performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type. This review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels. The findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
PurposeTo identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review.MethodsWe performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type.ResultsThis review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels.ConclusionThe findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
Purpose To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review. Methods We performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type. Results This review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels. Conclusion The findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
Abstract Purpose To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma (DLBCL) through a systematic literature review. Methods We performed a systematic literature review to identify factors impacting the efficacy and safety of CAR-T therapies in DLBCL. Articles were searched in PubMed, Cochrane, and EMBASE databases. Key outcomes, including progression-free survival (PFS), overall survival (OS), complete response rate (CRR), objective response rate (ORR), duration of response (DoR), best overall response (BOR), and safety measures (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS], and Cytokine Release Syndrome [CRS]), were extracted according to PRISMA guidelines. A total of 712 articles were identified, with 185 selected for full-text screening. Ultimately, 79 articles met inclusion criteria. Exclusions were primarily due to the absence of relevant outcome data or publication type. Results This review highlights several factors that may influence the efficacy and safety of CAR-T therapies in DLBCL, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), International Prognostic Index (IPI) score, disease histology, Ann Arbor disease stage, and elevated LDH levels. Conclusion The findings of this review can assist clinicians in refining treatment strategies and improving patient outcomes in DLBCL by incorporating these key influencing factors.
ArticleNumber 203
Author Borchmann, Peter
Mahlich, Jörg
Heger, Jan-Michel
Riou, Sybille
Schleifenbaum, Julia K.
Rosato, Umberto
Walzer, Stefan
Jost, Jonas
Author_xml – sequence: 1
  givenname: Julia K.
  surname: Schleifenbaum
  fullname: Schleifenbaum, Julia K.
  organization: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne
– sequence: 2
  givenname: Jan-Michel
  surname: Heger
  fullname: Heger, Jan-Michel
  organization: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne
– sequence: 3
  givenname: Jonas
  surname: Jost
  fullname: Jost, Jonas
  organization: MArS Market Access & Pricing Strategy GmbH
– sequence: 4
  givenname: Umberto
  surname: Rosato
  fullname: Rosato, Umberto
  organization: Miltenyi Biomedicine
– sequence: 5
  givenname: Sybille
  surname: Riou
  fullname: Riou, Sybille
  organization: Miltenyi Biomedicine
– sequence: 6
  givenname: Peter
  surname: Borchmann
  fullname: Borchmann, Peter
  organization: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne
– sequence: 7
  givenname: Stefan
  surname: Walzer
  fullname: Walzer, Stefan
  organization: MArS Market Access & Pricing Strategy GmbH, State University Baden-Wuerttemberg, University of Applied Sciences Weingarten-Ravensburg
– sequence: 8
  givenname: Jörg
  surname: Mahlich
  fullname: Mahlich, Jörg
  email: Joerg.Mahlich@gmail.com
  organization: Miltenyi Biomedicine, DICE, Heinrich-Heine-University Düsseldorf
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40619472$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAYhSNURC_wAiyQJTZsArZjx8kK0RGXSpVYUNaWx_mdcZXYwXaK0kfiKfFMSmlZsPLtO8dHv85pceS8g6J4SfBbgrF4FzFmFS0x5SWuKWvL2yfFCdlfkariRw_2x8VpjNcYE8EFfVYcM1yTlgl6Uvz6tsQEo0pWo8EmCCrNAVCAGws_UfLIduCSNQuagu-dj3vQKJ18iMgbBMZYrfSClOtQVAbSgvyctB_h8K53doSQNSq79OCys4Ypq9FVuYFhQGmX_5xspq1DnTVmjoAGFXpA5ysxLOO086N6Xjw1aojw4m49K75_-ni1-VJefv18sflwWWrWslQ2dcc1VFi0QtO2YfnAOWNcVVrV2y1ndAu8oaJTkKNoopqm6SpB21a3tGWkOisuVt_Oq2s5BTuqsEivrDxc-NBLFfIYBpCE0FoBBtNhxnBTqxo6BgYL2GLgTGSv96vXNG9H6HSeZVDDI9PHL87uZO9vJKE0J6r3ad7cOQT_Y4aY5GijznNRDvwcZUWpqCvesCqjr_9Br_0cXJ7VgWJ1w8Te8NXDSPdZ_nQiA3QFdPAxBjD3CMFyXzy5Fk_m4slD8eRtFlWrKGbY9RD-_v0f1W-HBd8N
Cites_doi 10.3389/fimmu.2020.565236
10.1089/jir.2021.0057
10.1200/JCO.19.02104
10.1186/s40425-018-0460-5
10.1016/S1470-2045(21)00375-2
10.1148/radiol.2021210760
10.3324/haematol.2021.278288
10.1158/1078-0432.CCR-20-1434
10.1053/j.seminoncol.2010.04.001
10.1200/JCO.2016.71.3024
10.1038/s41408-019-0247-z
10.5045/br.2022.2022055
10.1007/s40487-022-00211-6
10.1182/bloodadvances.2022009426
10.3389/fimmu.2022.877477
10.3390/cancers13174279
10.1007/s12149-020-01544-w
10.1080/10428194.2021.1975188
10.3390/cancers15061747
10.3390/cancers15174253
10.1182/blood.2018883421
10.3324/haematol.2022.280805
10.1158/1078-0432.CCR-20-1457
10.1182/blood.2023020197
10.1182/hematology.2023000436
10.1002/cncr.34532
10.1111/jcmm.17550
10.1002/ajh.26718
10.1182/blood-2023-184862
10.1136/jitc-2022-006406
10.1056/NEJMoa2115304
10.1016/j.clml.2022.05.004
10.1200/JCO.19.02103
10.1007/s11912-016-0539-4
10.1182/bloodadvances.2020002118
10.1136/bmj.n71
10.1080/10428194.2020.1849676
10.1093/neuonc/noaa183
10.1097/JTO.0b013e318292bdcd
10.1182/bloodadvances.2023011489
10.1182/bloodadvances.2020002228
10.1182/bloodadvances.2023010364
10.1182/bloodadvances.2023010127
10.1038/s41467-020-14612-6
10.1182/bloodadvances.2021004575
10.1200/JCO.21.02143
10.1007/s10147-023-02334-w
10.1016/j.jcyt.2022.10.010
10.1182/bloodadvances.2022008937
10.3390/cancers15174334
10.1002/ajh.25951
10.1001/jamaoncol.2022.3738
10.1182/blood.2019004162
10.1200/JCO.20.01467
10.1182/blood.2022015601
10.3390/cancers17081335
10.1182/bloodadvances.2020003959
10.3390/ijms24065688
10.1182/bloodadvances.2019000525
10.1016/j.hemonc.2021.09.001
10.1182/blood.2020008865
10.1016/j.ijrobp.2021.06.038
10.1002/cam4.3881
10.1182/bloodadvances.2021006144
10.1016/j.jtct.2022.05.026
10.3390/jcm12072553
10.3389/fimmu.2022.855730
10.1056/NEJMoa1707447
10.3390/cancers15184671
10.1111/ejh.13968
10.1182/bloodadvances.2020002394
10.1038/s41591-022-01969-y
10.1111/ejh.13609
10.1016/S0140-6736(20)31366-0
10.1016/S2352-3026(17)30108-4
10.1200/JCO.21.00377
10.1158/2326-6066.CIR-22-0487
10.1056/NEJMoa2116133
10.1182/blood-2018-12-893396
10.2147/CMAR.S321202
10.1038/s41591-022-01916-x
10.1182/bloodadvances.2020003036
10.1016/j.clml.2021.07.002
10.1016/j.xcrm.2023.101158
10.1097/HS9.0000000000000907
10.1182/bloodadvances.2021006563
10.1111/bjh.18335
10.1182/bloodadvances.2020001972
10.1056/NEJMoa2116596
10.3390/biom13020382
10.1080/10428194.2021.1986216
10.3390/cancers15092411
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2025 2025
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2025 2025
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TO
H94
K9.
7X8
5PM
DOA
DOI 10.1007/s00432-025-06249-z
DatabaseName Springer Nature Link
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1335
EndPage 18
ExternalDocumentID oai_doaj_org_article_1126ae0efd044086a6ed4ef07eb0e547
PMC12229961
40619472
10_1007_s00432_025_06249_z
Genre Systematic Review
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Miltenyi Biotec
  funderid: https://doi.org/10.13039/501100004176
GroupedDBID ---
-~X
.86
.VR
06C
06D
0R~
0VY
199
1N0
203
29K
29~
2J2
2JY
2KG
2KM
2LR
2~H
30V
36B
4.4
406
408
409
40D
40E
5RE
5VS
67Z
6NX
78A
8UJ
95-
95.
95~
96X
AABHQ
AAFWJ
AAHNG
AAIAL
AAJKR
AAJSJ
AAKKN
AANZL
AARTL
AASML
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYZH
ABBBX
ABBXA
ABDBE
ABDZT
ABECU
ABEEZ
ABFSG
ABFTV
ABHLI
ABHQN
ABIPD
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABSXP
ABTKH
ABTMW
ABWNU
ABXPI
ACACY
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACSTC
ACULB
ADBBV
ADHHG
ADHIR
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFGXO
AFHIU
AFLOW
AFPKN
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIIXL
AILAN
AITGF
AIXLP
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AYFIA
AZFZN
B-.
BA0
BENPR
BGNMA
C24
C6C
CS3
CSCUP
D-I
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EMB
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FNLPD
FRRFC
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GQ8
GROUPED_DOAJ
GXS
HF~
HG5
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAS
LLZTM
M2O
M4Y
MA-
N9A
NB0
NPVJJ
NQJWS
NU0
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PT5
QOK
QOR
QOS
R89
R9I
RHV
ROL
RPM
RPX
RRX
RSV
S16
S1Z
S27
S37
S3B
SAP
SDH
SDM
SHX
SISQX
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
T13
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UOJIU
UTJUX
VC2
W23
W48
WJK
WK8
YLTOR
Z45
ZMTXR
ZOVNA
~EX
~KM
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TO
H94
K9.
7X8
ABTEG
5PM
ID FETCH-LOGICAL-c494t-86d5ce30797c29845ce55445a3ca6bb542be5827daeecec1a888d37299c929413
IEDL.DBID DOA
ISSN 1432-1335
0171-5216
IngestDate Wed Aug 27 01:31:28 EDT 2025
Thu Aug 21 18:23:40 EDT 2025
Fri Sep 05 15:43:34 EDT 2025
Sat Aug 16 21:33:35 EDT 2025
Sat Aug 16 01:30:53 EDT 2025
Thu Aug 21 00:24:17 EDT 2025
Fri Aug 15 01:11:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords DLBCL
CAR-T
Prognostic factors
Systematic literature review
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c494t-86d5ce30797c29845ce55445a3ca6bb542be5827daeecec1a888d37299c929413
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://doaj.org/article/1126ae0efd044086a6ed4ef07eb0e547
PMID 40619472
PQID 3227468471
PQPubID 47182
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_1126ae0efd044086a6ed4ef07eb0e547
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12229961
proquest_miscellaneous_3227635843
proquest_journals_3227468471
pubmed_primary_40619472
crossref_primary_10_1007_s00432_025_06249_z
springer_journals_10_1007_s00432_025_06249_z
PublicationCentury 2000
PublicationDate 2025-07-07
PublicationDateYYYYMMDD 2025-07-07
PublicationDate_xml – month: 07
  year: 2025
  text: 2025-07-07
  day: 07
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Journal of cancer research and clinical oncology
PublicationTitleAbbrev J Cancer Res Clin Oncol
PublicationTitleAlternate J Cancer Res Clin Oncol
PublicationYear 2025
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Springer
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
– name: Springer
References O Beyar Katz (6249_CR8) 2023; 111
AC Wood (6249_CR94) 2022; 28
H Goto (6249_CR33) 2023; 28
P Strati (6249_CR89) 2021; 137
JC Zurko (6249_CR98) 2022; 97
6249_CR70
P Karschnia (6249_CR48) 2019; 133
ST Bhaskar (6249_CR9) 2023; 7
N Scholler (6249_CR78) 2022; 28
A Mussetti (6249_CR64) 2023; 2023
P Strati (6249_CR90) 2023; 4
6249_CR87
DJ Landsburg (6249_CR56) 2023; 29
SJ Schuster (6249_CR80) 2021; 22
P Sesques (6249_CR82) 2020; 95
OH Butt (6249_CR16) 2022; 8
G Iacoboni (6249_CR41) 2021; 10
FA Ayuk (6249_CR4) 2021; 5
K Rejeski (6249_CR72) 2023; 11
P Borchmann (6249_CR12) 2023; 11
MM Boyiadzis (6249_CR14) 2018; 6
X Dang (6249_CR20) 2023; 25
M Bastos-Oreiro (6249_CR6) 2022; 13
CS Sauter (6249_CR75) 2019; 134
MR Bishop (6249_CR10) 2022; 386
NG Holtzman (6249_CR40) 2021; 23
S Halabi (6249_CR39) 2010; 37
S Lamure (6249_CR55) 2021; 13
V Bücklein (6249_CR15) 2023; 7
A Di Rocco (6249_CR23) 2021; 62
T Lakomy (6249_CR54) 2023; 13
WA Bethge (6249_CR7) 2022; 140
P Dreger (6249_CR25) 2020; 4
LJ Nastoupil (6249_CR65) 2020; 38
P Strati (6249_CR88) 2020; 4
CA Jacobson (6249_CR44) 2020; 38
M Garcia-Recio (6249_CR30) 2021; 27
JN Kochenderfer (6249_CR50) 2017; 35
M Melody (6249_CR62) 2021; 107
D Chihara (6249_CR19) 2023; 142
F Korell (6249_CR51) 2022; 13
M Kwon (6249_CR52) 2023; 108
A Guidetti (6249_CR38) 2023; 129
K Wudhikarn (6249_CR95) 2020; 4
FL Locke (6249_CR59) 2020; 4
MJ Page (6249_CR69) 2021; 372
JS Abramson (6249_CR1) 2020; 396
L Simms (6249_CR85) 2013; 8
T Luft (6249_CR61) 2017; 4
D Sermer (6249_CR81) 2020; 4
H Liu (6249_CR58) 2021; 27
FL Locke (6249_CR60) 2022; 386
L Iovino (6249_CR42) 2022; 26
OS Akhtar (6249_CR2) 2023; 7
V Blumenberg (6249_CR11) 2023; 7
SS Neelapu (6249_CR67) 2017; 377
A Schaefer (6249_CR76) 2021; 13
M Khalil (6249_CR49) 2020; 11
MJ Frank (6249_CR29) 2021; 39
M Gotti (6249_CR34) 2020; 11
H Zhang (6249_CR97) 2022; 63
KM Cappell (6249_CR17) 2020; 38
S Ghafouri (6249_CR32) 2021; 21
U Greenbaum (6249_CR35) 2021; 5
F Schoeberl (6249_CR77) 2022; 6
JV Forero-Forero (6249_CR28) 2023; 16
R Ram (6249_CR71) 2022; 107
R Shouval (6249_CR84) 2022; 40
K Nath (6249_CR66) 2022; 28
L Shargian (6249_CR83) 2022; 198
DA Smith (6249_CR86) 2022; 302
G Kanas (6249_CR47) 2022; 63
C Ladbury (6249_CR53) 2023; 15
E Bourbon (6249_CR13) 2023; 7
MT Jacobs (6249_CR43) 2022; 22
A Merz (6249_CR63) 2019; 9
E Gavriilaki (6249_CR31) 2023; 15
MD Jain (6249_CR46) 2024; 8
PA Riedell (6249_CR73) 2023; 142
B Guffroy (6249_CR37) 2024; 422346
CA Jacobson (6249_CR45) 2022; 28
V Wittibschlager (6249_CR93) 2023; 24
HJJ Cherng (6249_CR18) 2022; 140
S Riou (6249_CR74) 2025; 17
A Trando (6249_CR92) 2023; 15
E Bachy (6249_CR5) 2022; 28
R Awasthi (6249_CR3) 2020; 4
R Dong (6249_CR24) 2021; 41
D Schult (6249_CR79) 2023; 12
T Derlin (6249_CR22) 2021; 35
SS Neelapu (6249_CR68) 2020; 135
EA Dean (6249_CR21) 2023; 7
H Tilly (6249_CR91) 2022; 386
KH Yoo (6249_CR96) 2022; 57
NB Figura (6249_CR27) 2021; 111
R Faramand (6249_CR26) 2020; 26
A Guarini (6249_CR36) 2023; 15
H Lennon (6249_CR57) 2016; 18
References_xml – volume: 11
  start-page: 565236
  year: 2020
  ident: 6249_CR34
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.565236
– volume: 41
  start-page: 469
  year: 2021
  ident: 6249_CR24
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/jir.2021.0057
– volume: 38
  start-page: 3119
  year: 2020
  ident: 6249_CR65
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.02104
– volume: 6
  start-page: 137
  year: 2018
  ident: 6249_CR14
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0460-5
– volume: 22
  start-page: 1403
  year: 2021
  ident: 6249_CR80
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00375-2
– volume: 302
  start-page: 438
  year: 2022
  ident: 6249_CR86
  publication-title: Radiology
  doi: 10.1148/radiol.2021210760
– volume: 107
  start-page: 1111
  year: 2022
  ident: 6249_CR71
  publication-title: Haematologica
  doi: 10.3324/haematol.2021.278288
– volume: 26
  start-page: 4823
  year: 2020
  ident: 6249_CR26
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1434
– volume: 37
  start-page: E9
  year: 2010
  ident: 6249_CR39
  publication-title: Semin Oncol
  doi: 10.1053/j.seminoncol.2010.04.001
– volume: 35
  start-page: 1803
  year: 2017
  ident: 6249_CR50
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.71.3024
– volume: 9
  start-page: 85
  year: 2019
  ident: 6249_CR63
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-019-0247-z
– volume: 57
  start-page: 75
  year: 2022
  ident: 6249_CR96
  publication-title: Blood Res
  doi: 10.5045/br.2022.2022055
– volume: 11
  start-page: 65
  year: 2023
  ident: 6249_CR12
  publication-title: Oncol Ther
  doi: 10.1007/s40487-022-00211-6
– volume: 7
  start-page: 4608
  year: 2023
  ident: 6249_CR21
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2022009426
– volume: 28
  start-page: 751.E1
  year: 2022
  ident: 6249_CR66
  publication-title: Trans Cell Therapy
– volume: 13
  start-page: 877477
  year: 2022
  ident: 6249_CR51
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.877477
– volume: 13
  start-page: 4279
  issue: 17
  year: 2021
  ident: 6249_CR55
  publication-title: Cancers
  doi: 10.3390/cancers13174279
– volume: 35
  start-page: 132
  year: 2021
  ident: 6249_CR22
  publication-title: Ann Nucl Med
  doi: 10.1007/s12149-020-01544-w
– volume: 63
  start-page: 54
  year: 2022
  ident: 6249_CR47
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428194.2021.1975188
– volume: 15
  start-page: 1747
  issue: 6
  year: 2023
  ident: 6249_CR53
  publication-title: Cancers
  doi: 10.3390/cancers15061747
– volume: 15
  start-page: 4253
  issue: 17
  year: 2023
  ident: 6249_CR31
  publication-title: Cancers
  doi: 10.3390/cancers15174253
– volume: 134
  start-page: 626
  year: 2019
  ident: 6249_CR75
  publication-title: Blood
  doi: 10.1182/blood.2018883421
– volume: 108
  start-page: 110
  year: 2023
  ident: 6249_CR52
  publication-title: Haematologica
  doi: 10.3324/haematol.2022.280805
– volume: 27
  start-page: 473
  year: 2021
  ident: 6249_CR58
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1457
– volume: 142
  start-page: 1047
  year: 2023
  ident: 6249_CR19
  publication-title: Blood
  doi: 10.1182/blood.2023020197
– volume: 2023
  start-page: 357
  year: 2023
  ident: 6249_CR64
  publication-title: Hematology Am Soc Hematol Educ Program
  doi: 10.1182/hematology.2023000436
– volume: 129
  start-page: 255
  year: 2023
  ident: 6249_CR38
  publication-title: Cancer
  doi: 10.1002/cncr.34532
– volume: 26
  start-page: 5976
  year: 2022
  ident: 6249_CR42
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.17550
– volume: 97
  start-page: 1580
  year: 2022
  ident: 6249_CR98
  publication-title: Am J Hematol
  doi: 10.1002/ajh.26718
– volume: 142
  start-page: 617
  year: 2023
  ident: 6249_CR73
  publication-title: Blood
  doi: 10.1182/blood-2023-184862
– ident: 6249_CR70
  doi: 10.1136/jitc-2022-006406
– volume: 386
  start-page: 351
  year: 2022
  ident: 6249_CR91
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2115304
– volume: 22
  start-page: 753
  year: 2022
  ident: 6249_CR43
  publication-title: Clin Lymphoma Myeloma Leukemia
  doi: 10.1016/j.clml.2022.05.004
– volume: 38
  start-page: 3095
  year: 2020
  ident: 6249_CR44
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.02103
– volume: 18
  start-page: 56
  year: 2016
  ident: 6249_CR57
  publication-title: Curr Oncol Rep
  doi: 10.1007/s11912-016-0539-4
– volume: 4
  start-page: 4669
  year: 2020
  ident: 6249_CR81
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020002118
– volume: 140
  start-page: 349
  year: 2022
  ident: 6249_CR7
  publication-title: Blood
– volume: 372
  start-page: N71
  year: 2021
  ident: 6249_CR69
  publication-title: BMJ
  doi: 10.1136/bmj.n71
– volume: 62
  start-page: 828
  year: 2021
  ident: 6249_CR23
  publication-title: Leukemia Lymphoma
  doi: 10.1080/10428194.2020.1849676
– volume: 23
  start-page: 112
  year: 2021
  ident: 6249_CR40
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noaa183
– volume: 29
  start-page: 495
  year: 2023
  ident: 6249_CR56
  publication-title: Trans Cell Therapy
– volume: 8
  start-page: 808
  year: 2013
  ident: 6249_CR85
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318292bdcd
– volume: 8
  start-page: 1042
  year: 2024
  ident: 6249_CR46
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2023011489
– volume: 4
  start-page: 3943
  year: 2020
  ident: 6249_CR88
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020002228
– volume: 28
  start-page: 8291
  year: 2022
  ident: 6249_CR94
  publication-title: Trans Cell Therapy
– volume: 7
  start-page: 6844
  issue: 22
  year: 2023
  ident: 6249_CR11
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2023010364
– volume: 7
  start-page: 5937
  issue: 19
  year: 2023
  ident: 6249_CR2
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2023010127
– volume: 11
  start-page: 812
  year: 2020
  ident: 6249_CR49
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-14612-6
– volume: 5
  start-page: 2799
  year: 2021
  ident: 6249_CR35
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2021004575
– volume: 40
  start-page: 369
  year: 2022
  ident: 6249_CR84
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.02143
– volume: 28
  start-page: 816
  year: 2023
  ident: 6249_CR33
  publication-title: Int J Clin Oncol
  doi: 10.1007/s10147-023-02334-w
– volume: 25
  start-page: 573
  year: 2023
  ident: 6249_CR20
  publication-title: Cytotherapy
  doi: 10.1016/j.jcyt.2022.10.010
– volume: 7
  start-page: 4765
  year: 2023
  ident: 6249_CR9
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2022008937
– ident: 6249_CR87
  doi: 10.3390/cancers15174334
– volume: 95
  start-page: 1324
  year: 2020
  ident: 6249_CR82
  publication-title: Am J Hematol
  doi: 10.1002/ajh.25951
– volume: 8
  start-page: 1652
  year: 2022
  ident: 6249_CR16
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2022.3738
– volume: 135
  start-page: 2106
  year: 2020
  ident: 6249_CR68
  publication-title: Blood
  doi: 10.1182/blood.2019004162
– volume: 38
  start-page: 3805
  year: 2020
  ident: 6249_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.01467
– volume: 140
  start-page: 504
  year: 2022
  ident: 6249_CR18
  publication-title: Blood
  doi: 10.1182/blood.2022015601
– volume: 17
  start-page: 1335
  issue: 8
  year: 2025
  ident: 6249_CR74
  publication-title: Cancers
  doi: 10.3390/cancers17081335
– volume: 5
  start-page: 2523
  issue: 11
  year: 2021
  ident: 6249_CR4
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020003959
– volume: 24
  start-page: 5688
  issue: 6
  year: 2023
  ident: 6249_CR93
  publication-title: Intern J Molecular Sci
  doi: 10.3390/ijms24065688
– volume: 4
  start-page: 560
  issue: 3
  year: 2020
  ident: 6249_CR3
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2019000525
– volume: 16
  start-page: 133
  year: 2023
  ident: 6249_CR28
  publication-title: Hematol Oncol Stem Cell Ther
  doi: 10.1016/j.hemonc.2021.09.001
– volume: 137
  start-page: 3272
  year: 2021
  ident: 6249_CR89
  publication-title: Blood
  doi: 10.1182/blood.2020008865
– volume: 111
  start-page: 1145
  year: 2021
  ident: 6249_CR27
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2021.06.038
– volume: 10
  start-page: 3214
  year: 2021
  ident: 6249_CR41
  publication-title: Cancer Med
  doi: 10.1002/cam4.3881
– volume: 6
  start-page: 3022
  year: 2022
  ident: 6249_CR77
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2021006144
– volume: 28
  start-page: 581.E1
  year: 2022
  ident: 6249_CR45
  publication-title: Transplant Cell Ther
  doi: 10.1016/j.jtct.2022.05.026
– volume: 12
  start-page: 2553
  issue: 7
  year: 2023
  ident: 6249_CR79
  publication-title: J Clin Med
  doi: 10.3390/jcm12072553
– volume: 13
  start-page: 855730
  year: 2022
  ident: 6249_CR6
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.855730
– volume: 377
  start-page: 2531
  year: 2017
  ident: 6249_CR67
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1707447
– volume: 15
  start-page: 4671
  issue: 18
  year: 2023
  ident: 6249_CR92
  publication-title: Cancers
  doi: 10.3390/cancers15184671
– volume: 111
  start-page: 63
  year: 2023
  ident: 6249_CR8
  publication-title: Eur J Haematol
  doi: 10.1111/ejh.13968
– volume: 27
  start-page: 233
  year: 2021
  ident: 6249_CR30
  publication-title: Trans Cell Therapy
– volume: 4
  start-page: 4898
  year: 2020
  ident: 6249_CR59
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020002394
– volume: 28
  start-page: 2145
  year: 2022
  ident: 6249_CR5
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01969-y
– volume: 107
  start-page: 48
  year: 2021
  ident: 6249_CR62
  publication-title: Eur J Haematol
  doi: 10.1111/ejh.13609
– volume: 396
  start-page: 839
  year: 2020
  ident: 6249_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31366-0
– volume: 4
  start-page: E414
  year: 2017
  ident: 6249_CR61
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(17)30108-4
– volume: 39
  start-page: 3034
  year: 2021
  ident: 6249_CR29
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.00377
– volume: 11
  start-page: 707
  year: 2023
  ident: 6249_CR72
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-22-0487
– volume: 386
  start-page: 640
  year: 2022
  ident: 6249_CR60
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2116133
– volume: 133
  start-page: 2212
  year: 2019
  ident: 6249_CR48
  publication-title: Blood
  doi: 10.1182/blood-2018-12-893396
– volume: 13
  start-page: 8901
  year: 2021
  ident: 6249_CR76
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S321202
– volume: 28
  start-page: 1872
  year: 2022
  ident: 6249_CR78
  publication-title: Nat Med
  doi: 10.1038/s41591-022-01916-x
– volume: 4
  start-page: 6157
  year: 2020
  ident: 6249_CR25
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020003036
– volume: 21
  start-page: 861
  year: 2021
  ident: 6249_CR32
  publication-title: Clin Lymphoma Myeloma Leukemia
  doi: 10.1016/j.clml.2021.07.002
– volume: 422346
  start-page: S242
  year: 2024
  ident: 6249_CR37
  publication-title: EHA Library
– volume: 4
  start-page: 101158
  issue: 8
  year: 2023
  ident: 6249_CR90
  publication-title: Cell Rep Med
  doi: 10.1016/j.xcrm.2023.101158
– volume: 7
  start-page: E907
  year: 2023
  ident: 6249_CR15
  publication-title: Hemasphere
  doi: 10.1097/HS9.0000000000000907
– volume: 7
  start-page: 744
  year: 2023
  ident: 6249_CR13
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2021006563
– volume: 198
  start-page: 838
  year: 2022
  ident: 6249_CR83
  publication-title: Br J Haematol
  doi: 10.1111/bjh.18335
– volume: 4
  start-page: 3024
  year: 2020
  ident: 6249_CR95
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2020001972
– volume: 386
  start-page: 629
  year: 2022
  ident: 6249_CR10
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2116596
– volume: 13
  start-page: 382
  issue: 2
  year: 2023
  ident: 6249_CR54
  publication-title: Biomolecules
  doi: 10.3390/biom13020382
– volume: 63
  start-page: 353
  year: 2022
  ident: 6249_CR97
  publication-title: Leukemia Lymphoma
  doi: 10.1080/10428194.2021.1986216
– volume: 15
  start-page: 2411
  issue: 9
  year: 2023
  ident: 6249_CR36
  publication-title: Cancers
  doi: 10.3390/cancers15092411
SSID ssj0017572
Score 2.433165
SecondaryResourceType review_article
Snippet Purpose To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell...
To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell lymphoma...
PurposeTo identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large B-cell...
Abstract Purpose To identify and summarize clinical factors influencing the efficacy and safety outcomes of CAR-T cell therapies in patients with diffuse large...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 203
SubjectTerms Antigens
B-cell lymphoma
Cancer Research
CAR-T
Cell therapy
Chemotherapy
Chimeric antigen receptors
Cytokine storm
DLBCL
Hematology
Humans
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Internal Medicine
Literature reviews
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Large B-Cell, Diffuse - therapy
Medical prognosis
Medical Subject Headings-MeSH
Medicine
Medicine & Public Health
Neurotoxicity
Oncology
Patients
Prognosis
Prognostic factors
Receptors, Chimeric Antigen - immunology
Response rates
Review
Safety
Systematic literature review
Systematic review
Treatment Outcome
SummonAdditionalLinks – databaseName: SpringerLINK
  dbid: C24
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIhLRXk1UNAgcYNIaWLHyZGuqCqkcqGVeosce0xXCkm1mz1sfxK_khnngRbKoceNnY2V8XhmMvN9I8QHWZeqMIzM9WUSk0dsYmMzE3v0uXKeLG7gLTj_lp9dyq9X6moEha2navcpJRlO6hnsFtjjYm6_muQUNMS3D8UjRbE7N2xYMMZhzB1opdMRHnP3fTsmKDD13-Ve_lsl-VeqNFig06dif3Qd4fMg6wPxANtn4vH5mBx_Ln59n1mZoZnZkmEAp0DfwTKAcv0WuCir7ZihGcZ-O9B5QGaTMHYLpnWwNh77LXSbnt4OhnF7vQzpHRrvmcOT_plrYroVXMQLbBoYsFwUesOyBe68slkjNFxqDifDjGZLm6f7aV6Iy9MvF4uzeGzFEFtZyj4ucqcs0nlQapuWhaQfiml8TGZNXtdKpjWqItXOID3aHhsKrB1nBEtL_hcZypdir-1aPBTg08wmia9lJpGCS2O8wwx1phPlktRgJD5O0qluBsaNauZWDrKsSJZVkGV1G4kTFuA8k9myw4Vu9aMala9imJTBBL0LDbZzk6OT6BONdYJK6kgcTeKvRhVeV3TSaZmz8Y7E-3mYlI8zKqbFbjPMIY-tkFkkXg27ZV4Je0ql1Gkkip19tLPU3ZF2eR0Ivo-5yXqZ04M_TVvuz7r-_y5e32_6G_EkDVrB36qPxF6_2uBb8rD6-l1QqN_PtSPy
  priority: 102
  providerName: Springer Nature
Title Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma
URI https://link.springer.com/article/10.1007/s00432-025-06249-z
https://www.ncbi.nlm.nih.gov/pubmed/40619472
https://www.proquest.com/docview/3227468471
https://www.proquest.com/docview/3227635843
https://pubmed.ncbi.nlm.nih.gov/PMC12229961
https://doaj.org/article/1126ae0efd044086a6ed4ef07eb0e547
Volume 151
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSIgL4k2grIzEDSJcx3aS4-6qSwVqL3SlcoocZ6yulCaomz1sfxK_khknG1ge4sIlUWIrtjxjz0xm5hvG3qgy15mlzFyfixg1Yhtbl9jYgze68ihxA27B6Zk5WaqPF_rip1JfFBPWwwP3C_eeUlwsCPBVKI5srIFKgRcplAK0CnnkIhc7Y2rwH6Q6lUOKTEiUC8hzMZVuFQYNjvhmTwwFtP4_qZi_R0r-4i4NUmjxgN0f1Ec-7af9kN2C5hG7ezo4yB-zb59HZGZej4jJvE9Q4V3LVyEx1285BWY1LaE086HmDm89B0KUsG7LbVPxtfXQbXm76ZAtIbS7y1Vw8WB7Rzie-GWKi2mv-Xk8h7rmfT4Xmt981XCqvrJZA68p3JzP-h71FhmovbJP2HJxfD4_iYdyDLFTuerizFTaAZ4Jeepknil80ATlYxNnTVlqJUvQmUwrCzi0O7JoXFfkFcwd6mAoLJ-yg6Zt4DnjXiZOCF-qRAEamNb6ChJIk1ToSkgLEXu7o07xtUfdKEZ85UDLAmlZBFoWNxGbEQHHnoSYHV4gHxUDHxX_4qOIHe7IXwzbeF3gaZcqQwI8Yq_HZtyA5FWxDbSbvg9qbZlKIvas55ZxJqQt5SqVEcv2-GhvqvstzeoygHwfUaH13ODA73Ys92Nef1-LF_9jLV6yezLsFfqLfcgOuusNvELdqysn7M50MZud0f3Dl0_HE3Z7LhVdzXwStiBel3L6HRI-NUo
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELZgkYAL4k1gASNxg0hpYsfJkV2xKrDdC11pb5Zjj9lKIUFteuj-JH4lM84DFZYDx8ZOY2U8npnMfN8w9lZUpSwMIXN9mcToEZvY2MzEHnwunUeLG3gLFmf5_Fx8vpAXAyhsM1a7jynJcFJPYLfAHhdT-9Ukx6AhvrrJbokZRkGUoiWMw5A7UFKlAzzm-vv2TFBg6r_Ovfy7SvKPVGmwQCf32b3BdeQfelk_YDegechuL4bk-CP28-vEyszriS2Z9-AU3rV8FUC5fsepKKtpiaGZD_12eOs5EJuEsTtuGsc3xkO34-22w7cDYdxerkJ6B8c74vDEf6aamHbNl_Ex1DXvsVwYevNVw6nzynYDvKZSc37Uz6h3uHna7-YxOz_5uDyex0MrhtiKUnRxkTtpAc-DUtm0LAT-kETjYzJr8qqSIq1AFqlyBvDRdmYwsHaUESwt-l9oKJ-wg6Zt4BnjPs1skvhKZAIwuDTGO8hAZSqRLkkNROzdKB39o2fc0BO3cpClRlnqIEt9FbEjEuA0k9iyw4V2_U0PyqcJJmUgAe9Cg-3c5OAE-ERBlYAUKmKHo_j1oMIbjSedEjkZ74i9mYZR-SijYhpot_0c9NgKkUXsab9bppWQp1QKlUas2NtHe0vdH2lWl4Hge0ZN1sscH_x-3HK_1_Xvd_H8_6a_Znfmy8WpPv109uUFu5sGDaHv1ofsoFtv4SV6W131KijXL-XtJvA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBWXijcpBYzEDaKmie0kR7qwKo9WSLRSb5Zjj9uVQlLtZg_bn8SvZMbJBhbKgWNiJ7E8Hs84M983jL0WVSkLQ8hcXyYxesQmNjYzsQevpPNocQNvwfGJOjoTn87l-W8o_pDtvg5J9pgGYmlquv0r5_dH4FtgkoupFGui8AARX99mdwSZPgrXqskYR8hlng5QmZuf2zBHgbX_Jlfz74zJP8KmwRpN77GdwY3k73q532e3oHnAto-HQPlD9uPbyNDM65E5mfdAFd61fBYAun7FKUGraYmtmQ-1d3jrORCzhLErbhrHF8ZDt-LtssOZgtBuL2ch1IPtHfF54pspP6ad89N4AnXNe1wXHsP5rOFUhWW5AF5T2jk_7HvUK1xI7XfziJ1NP5xOjuKhLENsRSm6uFBOWsC9ocxtWhYCLyRR-pjMGlVVUqQVyCLNnQH8tD0weMh2FB0sLfpiaDQfs62mbeAp4z7NbJL4SmQCUHzGeAcZ5FmeSJekBiL2Zi0dfdWzb-iRZznIUqMsdZClvo7YIQlw7EnM2eFGO7_QgyJqgkwZSMC7UGxbGQVOgE9yqBKQIo_Y3lr8elDnhcZdLxeKDHnEXo3NqIgUXTENtMu-D3pvhcgi9qRfLeNIyGsqRZ5GrNhYRxtD3WxpZpeB7PuACq6XCj_8dr3kfo3r33Ox-3_dX7Ltr--n-svHk8_P2N00KAj9wt5jW918Cc_R8eqqF0G3fgI0dStK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systematic+literature+review+to+identify+prognostic+factors+of+efficacy+and+safety+outcomes+of+chimeric+antigen+receptor+T-Cell+therapies+in+diffuse+large+B-Cell+lymphoma&rft.jtitle=Journal+of+cancer+research+and+clinical+oncology&rft.au=Julia+K.+Schleifenbaum&rft.au=Jan-Michel+Heger&rft.au=Jonas+Jost&rft.au=Umberto+Rosato&rft.date=2025-07-07&rft.pub=Springer&rft.eissn=1432-1335&rft.volume=151&rft.issue=7&rft.spage=1&rft.epage=18&rft_id=info:doi/10.1007%2Fs00432-025-06249-z&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1126ae0efd044086a6ed4ef07eb0e547
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1432-1335&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1432-1335&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1432-1335&client=summon